Obesity Guidance Should Be More Lenient On Indications, Firms Tell FDA

A stipulation that patients should fail lifestyle modifications before they are eligible to enroll in clinical trials for obesity drugs needs to be modified, according to industry comments on an FDA draft guidance on development of weight management drugs